Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-RAF-1 kinase expression

Drug Metabolism and Disposition

Volumn 25, Issue 11, 1997, Pages 1272-1281

  Geary, Richard S ^a   Leeds, Janet M ^b   Fitchett, Jon ^b   Burckin, Todd ^b   Truong, Loanne ^b   Spainhour, Charles ^b   Creek, Moire ^b   Levin, Arthur A ^b  

^a ISIS PHARMACEUTICALS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; CGP 69846A; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG HALF LIFE; ENZYME INHIBITION; GROWTH INHIBITION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION; URINARY EXCRETION;

ANIMALS; AREA UNDER CURVE; BIOTRANSFORMATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HALF-LIFE; MALE; MICE; MICE, INBRED ICR; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-RAF; THIONUCLEOTIDES; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 0030667690     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. B. P. Monia, J. F. Johnston, T. Geiger, M. Muller, and D. Fabbro: Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med. 2, 668-675 (1996).
2. H. Sands, L. J. Gorey-Feret, A. J. Cocuzza, F. W. Hobbs, D. Chidester, and G. L. Trainor: Biodistribution and metabolism of internally 3H-labeled oligonucleotides: I. comparison of a phosphodiester and phosphorothioate. Md. Pharmacol. 45, 932-943 (1994).
3. R. Zhang, Z. Lu, H. Zhao, X. Zhang, R. Diasio, I. Habus, Z. Jiang, R. P. Iyer, D. Yu, and S. Agrawal: In vivo stability, disposition and metabolism of a "hybrid" oligonucleoitde phosphorothioate in rats. Biochem. Pharmacol. 50, 545-556 (1995).
4. S. Agrawal, J. Temsamani, W. Galbraith, and J. Tang: Pharmacoketics of antisense oligonucleotides. Clin. Pharmacokinet. 8, 7-16 (1995).
5. R. Zhang, J. Van, H. Shahinian, G. Amin, Z. Lu, T. Liu, M. S. Saag, Z. Jiang, J. Temsamani, R. Martin, P. J. Schechter, S. Agrawal, and R. B. Diasio: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin. Parmacol. Ther. 45-53 (1995).
6. E. Bayever, P. L. Iversen, M. R. Bishop, J. G. Sharp, H. K. Tewary, M. A. Arneson, S. J. Pirruccello, R. W. Ruddon, A. Kessinger, G. Zon, and J. O. Armitage: Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase 1 trial. Antisense Res. Dev. 383-390 (1993).
7. S. Agrawal, J. Temsamani, and J. Y. Tang: Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. U.S.A. 88, 7595-7599 (1991).
8. P. L. Iversen, J. Mata, W. G. Tracewell, and G. Zon: Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. Antisense Res. Dev. 4, 43-52 (1994).
9. P. A. Cossum, H. Sasmor, D. Dellinger, L. Troung, L. Cummins, S. R. Owens, P. M. Markham, J. P. Shea, and S. Crooke: Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267, 1181-1190 (1993).
10. P. A. Cossum, L. Troung, S. R. Owens, P. M. Markham, J. P. Shea, and S. T. Crooke: Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J. Pharmacol. Exp. Ther. 269, 89-94 (1994).
11. A. Rifai, W. Byrsch, K. Fadden, J. Clark, and K.-H. Schlingensipen: Clearance kinetics, biodistribution, and Organ saturability of phosphorothioate oligodeoxynucleotides in mice. Am. J. Pathol. 149, 717-725 (1996).
12. J. C. Bigelow, L. R. Chirin, L. A. Mathews, and J. J. McCormack: High-performance liquid chromatographic analysis of phosphorothioate analogues of oligodeoxynucleotides in biological fluids. J. Chromatogr. Biomed. Appl. 133-140 (1990).
13. M. J. Greig, H. Gaus, L. L. Cummins, H. Sasmor, and R. J. Griffey: Measurement of macromolecular binding using electrospray mass spectrometry: determination of disassociation constants for oligonucleotide-serum albumin complexes. J. Am. Chem Soc. 10765-10766 (1995).
14. D. F. Wu, R. J. Boado, and W. M. Pardridge: Pharmacokinetics and blood-brain barrier transport of [H-3]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. J. Pharmacol Exp. Ther. 276, 206-211 (1996).
15. R. Zhang, Z. Lu, X. Zhang, H. Zhao, R. B. Diasio, T. Liu, Z. Jiang, and S. Agrawal: In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats. Clin. Chem. 41, 836-843 (1995).
16. S. L. Beaucage, and R. P. Iyer: Advances in the synthesis of oligonucleotides by the phosphoramidite approach. Tetrahedron 48, 2223-2311 (1992).
17. R. P. Iyer, B. Uznanski, J. Boal, C. Storm, W. Egan, M. Matsukura, S. Broder, G. Zon, A. Wilk, M. Koziolkiewicz, and W. J. Stec: Abasic oligodeoxyribonucleoside phosphorothioates: synthesis and evaluation as anti-HIV-1 agents. Nucleic Acids Res. 18, 2855-2859 (1990).
18. J. M. Leeds, M. J. Graham, L. Truong, and L. L. Cummins: Quantitation of phosphorothioate oligonucleotides in human plasma. Anal. Biochem. 235, 36-43 (1996).
19. R. H. Griffey, M. J. Greig, H. J. Gaus, K. Liu, D. Monteith, M. Winniman, and L. L. Cummins: Characterization of oligonucleotide metabolism in vivo via liquid chromatography/electrospray tandem mass spectrometry with a quadropole ion trap mass spectrometer. J. Mass Spectrom. 32, 305-313,1997.
20. P. M. Burgers and F. Eckstein: A study of the mechanism of DNA polymerase I from Escherichia coli with diastereomeric phosphorothioate analogs of deoxyadenosine triphosphate. J. Biol Chem. (Tokyo) 254, 6889-6993 (1979).
21. S. Spitzer and F. Eckstein: Inhibition of deoxyribonucleases by phosphorothioate groups in oligodeoxyribonucleotide. Nucleic Acids Res. 16, 11691-11704 (1988).
22. J. A. Phillips, S. J. Craig, D. Bayley, R. A. Christian, R. Geary, and P. L. Nicklin: Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem. Pharmacol., 54, 657-668 (1997).
23. Y. Takakura, R. I. Mahato, M. Yoshida, T. Kanamaru, and M. Hashida: Uptake characteristics of oligonucleotides in the isolated rat liver perfusion system. Antisense Nucleic Acids Drug. Dev. 6, 177-183 (1996).
24. S. K. Srinivasan and P. Iversen: Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J. Clin. Lab. Anal. 9, 129-137 (1995).
25. G. Goodarzi: Organ distribution and stability of phosphorothioated oligodeoxyribonucleotides in mice. Biopharm. Drug Dispos. 13, 221-227 (1992).
26. J. Rappaport, B. Hanss, J. B. Kopp, T. D. Copelend, L. A. Bruggeman, T. M. Coffman, and P. E. Klotman: Transport of phosphorothioate oligonucleotide in kidney: implications for molecular therapy. Kidney Int. 47, 1462-1469 (1995).
27. F. Plenat, N. Klein-Monhoven, B. Marie, J.-M. Vignaud, and A. Duprez: Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice. Am. J. Pathol. 147, 124-135 (1994).
28. R. Oberbauer, G. F. Schreiner, and T. W. Meyer: Renal uptake of an 18-mer phosphorothioate oligonucleotide. Kidney Int. 48, 1226-1232 (1995).